BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 13, 2020
View Archived Issues
Endothelial cells have functional deficits in progeria
Read More
More enhancers suggest more pathogenicity: study
Read More
Tarsius opens two phase I/II trials of TRS-01 eye drops
Read More
Positive preclinical data presented for QPG-1029
Read More
Phase II data for arimoclomol as treatment of sporadic inclusion body myositis
Read More
Immunitor presents interim phase III data for hepcortespenlisimut-L in HCC
Read More
FASN as a new prognostic biomarker in Wilms' tumor
Read More
G-721-0282, novel CHI3L1 ligand with anti-proliferative effects in models of osteosarcoma
Read More
Chinese researchers patent PI3K inhibitors
Read More
Novartis identifies new NLRP3 inflammasome inhibitors
Read More
Japanese investigators synthesize new PTPN11 inhibitors
Read More
Hanmi Science describes new FLT3 and/or FLT3 ITD mutant inhibitors
Read More
New SNF2L2 inhibitors presented by Epizyme
Read More
ApoE, largest genetic risk factor for AD, also affects synucleinopathies
Read More
11 potential blockbuster drugs offer hope, threaten budgets
Read More
Tumor-targeted siRNA/pDNA dual delivery system reprograms the tumor microenvironment
Read More
Paraoxonase 1 gene therapy offers long-term protection against lethal doses of nerve agents in mice
Read More
Mucolipin-1 found to be a potential therapeutic target for DMD
Read More
Amgen studies AMG-509 in phase I for metastatic CRPC
Read More
PsiOxus initiates phase I study of NG-641 in metastatic or advanced epithelial tumors
Read More